The drug as a whole is well tolerated. Side effects are usually mild or moderate and are transient.
When assessing the incidence of side effects, the following grades are used: "Often" (≥ 1/10), "often" (≥1/100 <1/10), "infrequently" (≥1/1000 <1/100), "rarely" (≥1/10000 <1/1000), "rarely" (<1/10000), including individual messages.
Disorders from the hematopoiesis system: infrequently - anemia, very rarely - neutropenia, agranulocytosis, thrombocytopenia, pancytopenia.
Immune system disorders: very rarely - anaphylactoid reactions (including angioedema), cutaneous and systemic lupus erythematosus (or their exacerbation).
Disturbances from the nervous system: very often - headache; often - dizziness, flaws, up to their loss (usually recovery occurs within a few weeks after cessation of treatment); infrequently - paresthesia, hypoesthesia. There are separate reports of cases of long-term disturbances of taste sensations. In some cases, when taking the drug, depletion was noted.
Disorders of the psyche: often - Depression; infrequently anxiety.
Disturbances on the part of the organ of sight: infrequently - impaired vision.
Hearing disorders and labyrinthine disorders: infrequent - noise in the ears.
Disturbances from the liver and bile ducts: rarely - hepatobiliary dysfunction (mostly of the cholestatic nature), incl.hepatic failure, including very rare cases of serious liver failure (some with fatal outcome or requiring liver transplantation, in most cases, when developed liver failure, patients had serious concomitant systemic disease and the causal link of liver failure with taking terbinafine was doubtful) hepatitis, jaundice, cholestasis, increased activity of "liver" enzymes.
Disorders from the digestive system: very often - bloating, decreased appetite, indigestion, nausea, mild abdominal pain, diarrhea.
Disturbances from the skin and subcutaneous tissues: Very often - rash, urticaria, rarely - photosensitivity reactions; very rarely - Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, bullous dermatitis, psoriasiform skin rash or exacerbation of psoriasis, alopecia.
Disturbances from musculoskeletal and connective tissue: Often - arthralgia, myalgia.
General disorders: often - a feeling of fatigue; infrequent - an increase in body temperature.
Laboratory and instrumental data: infrequently - a decrease in body weight (secondary to the violation of taste sensations).
Based on the spontaneous messages received during the post-registration period and the literature data, the following undesirable phenomena were identified, the frequency of which due to an inaccurate number of patients can not be established:
Immune system disorders: anaphylactic reactions, a syndrome similar to serum sickness.
Disturbances on the part of the organ of sight: blurred vision, reduced visual acuity.
Disturbances from the skin and subcutaneous tissues: a drug rash with eosinophilia and systemic symptoms (rash, swelling, fever, and enlarged lymph nodes).
Hearing disorders and labyrinthine disorders: hearing loss, hearing impairment.
Violation of the vessels: vasculitis.
Violation of the nervous system: loss of smell, including for a long period of time, a decrease in the sense of smell.
Disorders from the digestive system: pancreatitis.
Disturbance of the side of the musculoskeletal and connective tissue: rhabdomyolysis.
General disorders: flu-like syndrome.
Violations of the blood and lymphatic system: anemia.
Laboratory and instrumental data: increased activity creatine phosphokinase in blood plasma.
If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.